Atomwise

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases. We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery. The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

neurons.bio is an AI application that offers a unique collection of over 100 AI agents designed for drug development, medicine, and life science research. These agents perform specific tasks efficiently, retrieve data from various sources, and provide insights to accelerate research processes. The platform aims to revolutionize drug discovery and development by integrating cutting-edge LLM technology with domain-specific agents, reducing research costs and time to clinic.

Komodo Health is a healthcare technology company that provides software applications to enable users to deliver exceptional value to their customers, colleagues, and patients. The company's Healthcare Map is the industry's most precise view of the U.S. healthcare system, and it combines the world's most comprehensive view of patient-encounters with innovative algorithms and decades of clinical expertise. Komodo Health's software applications are used by life sciences companies, payers, providers, and consultancies to improve the certainty of pre-launch plans, calculate Rx-based ROI for digital marketing, find patients with complicated or rare conditions, and more.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Simudyne is an enterprise simulation software powered by AI technology. It allows large financial institutions to simulate various future scenarios efficiently and measure their impact in a safe virtual environment. The software offers solutions for environment, social and governance issues, market execution, financial crime analytics, and risk management. Simudyne's technology is secure, distributable, and Cloudera certified, providing a robust library of code for specialized functions. The platform also utilizes agent-based modeling to bridge the gap between theoretical and real-world scenarios in the financial services sector.

Fathom5 is a company that specializes in the intersection of AI and industrial systems. They offer a range of products and services to help customers build more resilient, flexible, and efficient industrial systems. Fathom5's approach is unique in that they take a security-first approach to cyber-physical system design. This means that security is built into every stage of the development process, from ideation to engineering to testing to deployment. This approach has been proven to achieve higher system resiliency and faster regulatory compliance at a reduced cost.

SOMA is a Research Automation Platform that accelerates medical innovation by providing up to 100x speedup through process automation. The platform analyzes medical research articles, extracts important concepts, and identifies causal and associative relationships between them. It organizes this information into a specialized database forming a knowledge graph. Researchers can retrieve causal chains, access specific research articles, and perform tasks like concept analysis, drug repurposing, and target discovery. SOMA enhances literature review efficiency by finding relevant articles based on causal chains and keywords specified by the user. It empowers researchers to focus on their research by saving up to 95% of the time spent on pre-processing documents. The platform offers freemium access with extended functionality for 14 days and advanced features available through subscription.

Fathom5 is a company that specializes in the intersection of AI and industrial systems. They offer a range of products and services to help customers build the industrial systems of the future. Their solutions are focused on critical infrastructure, making it more resilient, flexible, and efficient.

Bloomberg is a leading global provider of financial data, news, and analytics. The company is known for its innovative technology solutions, including the Bloomberg Terminal, which revolutionized the industry by delivering critical insights and actionable information to financial decision-makers. Bloomberg is at the forefront of artificial intelligence, machine learning, and natural language processing, offering tools and automated workflows to help clients navigate the vast amount of data available in the financial markets. With a focus on engineering value for customers and keeping humans in the loop, Bloomberg continues to drive innovation and provide cutting-edge technology solutions for over 325,000 financial professionals worldwide.

PharmaTrace is an advanced healthcare ecosystem that utilizes blockchain technology and artificial intelligence to revolutionize the pharmaceutical industry. It offers solutions for track and trace, chronic disease forecasting, and digital transformation in the pharmaceutical supply chain. The platform aims to enhance business processes, improve patient care, and increase data security through innovative technologies. PharmaTrace provides customizable templates, scalable solutions, and easy access to blockchain-based technologies for pharmaceutical companies, pharmacies, insurances, and other stakeholders in the industry.

GenInnov is a generative innovation fund that provides a platform for investors seeking to be at the forefront of technological advancement. The fund invests in companies driving transformative change across multiple sectors and geographies, prioritizing material innovations with demonstrable profitability and global reach. GenInnov operates with a research-driven approach, focusing on investing in material innovations that are monetizable, profitable, and transformative, rather than incremental. The fund looks at various domains such as technology, robotics, consumer electronics, biotech, healthcare, mobility, and clean tech, aiming to amplify human creativity through machine intelligence.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Kuano is an AI tool that focuses on redefining drug discovery using Quantum and AI technologies. The platform offers world-class scientific expertise in quantum physics, AI, and medicinal chemistry to revolutionize the drug design process. Kuano aims to leverage cutting-edge technologies to accelerate the discovery of new drugs and improve healthcare outcomes.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Deepcell is a company that develops technology for single-cell analysis. Their REM-I platform combines label-free imaging, deep learning, and gentle sorting to leverage single cell morphology as a high-dimensional quantitative readout. This allows researchers to gain insights into cells' phenotype and function to address important research questions across biology.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Wildlife Insights is an AI application that brings cutting-edge technology to wildlife conservation. It streamlines decision-making by providing machine learning models and tools to manage, analyze, and share camera trap data. Users can easily upload, identify, analyze, and discover wildlife through the platform, enabling better decisions to help wildlife thrive globally.

BioloGPT is an AI tool designed to answer biology-related questions with insights and graphs. It provides information on various topics such as maintaining a healthy gut microbiome, foods for a healthy immune system, effects of cannabis on the brain, risks of Covid-19 vaccines, and advancements in psoriasis treatment. The tool is updated daily and cites full papers to support its answers.

Bichos ID de Fucesa is an AI tool that allows users to explore and identify insects, arachnids, and other arthropods using artificial intelligence. Users can discover the most searched bugs, explore new discoveries made by the community, and view curated organisms. The platform aims to expand knowledge about the fascinating world of arthropods through AI-powered identification.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Lavo Life Sciences is an AI-accelerated crystal structure prediction application that aims to accelerate drug development processes. The platform provides solutions for de-risking pipelines, optimizing solid-state formulations, and avoiding late-stage surprises using AI technology. Lavo Life Sciences combines the expertise of chemists and engineers in AI and computational chemistry to offer innovative solutions for drug development teams.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

C&EN, a publication of the American Chemical Society, provides the latest news and insights on the chemical industry, including research, technology, business, and policy. It covers a wide range of topics, including analytical chemistry, biological chemistry, business, careers, education, energy, environment, food, materials, people, pharmaceuticals, physical chemistry, policy, research integrity, safety, and synthesis.

CHAI AI Platform is an AI tool designed for quant traders to build and implement AI algorithms for trading. The platform combines chat functionality with AI capabilities to enhance the trading experience. Based in Palo Alto, CA, CHAI Research Corp. developed the platform to empower traders with advanced AI technology for better decision-making and performance in the financial markets.

SOMA is a Research Automation Platform that accelerates medical innovation by providing up to 100x speedup through process automation. The platform analyzes medical research articles, extracts important concepts, and identifies causal and associative relationships between them. It organizes this information into a specialized database forming a knowledge graph. Researchers can retrieve causal chains, access specific research articles, and perform tasks like concept analysis, drug repurposing, and target discovery. SOMA enhances literature review efficiency by finding relevant articles based on causal chains and keywords specified by the user. It empowers researchers to focus on their research by saving up to 95% of the time spent on pre-processing documents. The platform offers freemium access with extended functionality for 14 days and advanced features available through subscription.

Cambrian Copilot is an AI tool designed for researchers and engineers to easily stay up-to-date with the latest machine learning research. With over 240,000 ML papers available for search, the tool helps users understand complex details and automate literature reviews, simplifying the process of discovering and accessing cutting-edge research in the field of machine learning.

Mnemonic AI is an advanced Customer Intelligence AI tool that specializes in creating AI Personas and Digital Twin of the Customer. It helps organizations of all sizes better understand individuals by developing artificial intelligence solutions to tailor messages to their state of mind. The tool is fully automated, data-driven, and offers psychographics insights, integrations, and case studies to enhance customer centricity and marketing strategies.

functime is a time-series machine learning tool designed to perform forecasting at scale. It provides a comprehensive set of functions and resources to assist users in analyzing and evaluating time-series data. With features like scoring, ranking, and plotting functions, functime aims to simplify the process of forecasting and make it accessible to users of all levels of expertise. The tool also offers an API reference for developers looking to integrate time-series forecasting capabilities into their applications.

Kolank is an AI tool that provides a unified API for accessing a wide range of Language Model Models (LLMs) and providers. It offers features such as model comparison based on price, latency, output, context, and throughput, OpenAI compatible API integration, transparency in tracking API calls and token expenditure, cost reduction by paying for performance, load balancing with fallbacks, and easy integration with preferred LLMs using Python, Javascript, and Curl.

Promptmakr is a platform that facilitates the buying and selling of AI prompts. It serves as a marketplace where users can find and purchase prompts for various AI applications. The platform aims to streamline the process of acquiring prompts, making it easier for developers and AI enthusiasts to access high-quality content to enhance their projects.

StockGPT is an AI-powered financial research assistant that provides knowledge of earnings releases, financial reports, and fundamental information for S&P 500 and Nasdaq companies. It offers features like AI search, customizable filters, up-to-date data, industry research, and more to help users analyze companies and markets effectively.

Unlearn.ai is an AI-powered digital twins solution provider that optimizes clinical trials. Their TwinRCTs enable confident and quick clinical trials in various medical fields such as neuroscience, immunology, and metabolic diseases. By creating digital twins of patients, Unlearn.ai enhances the power and efficiency of clinical trials, attracting study participants and making confident decisions from early to late-stage studies.

Altera is an applied research lab focused on building digital human beings with fundamental human qualities. Led by Dr. Robert Yang, the team consists of computational neuroscientists, physics olympiads, and engineers from prestigious institutions. Their mission is to create digital beings that enhance human-to-human interactions, offering empathy, fun, friendship, and productivity at an unprecedented scale. Leveraging a state-of-the-art Composite Architecture inspired by the brain, Altera aims to develop agents with empathy, memory, and social norms. Starting with products in games, Altera plans to expand into multi-agent simulations and physical embodiment of digital intelligence, aspiring to become the most consequential technology company in the world.